NCT04431635 - Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

November 14, 2023

Study Completion Date

November 14, 2023

Conditions

Indolent Lymphoma

Interventions

DRUG

Copanlisib

Copanlisib IV: day 1, 8, 15 every 28 days

DRUG

Nivolumab

Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only

DRUG

Rituximab

Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)

Trial Locations (5)

University of Michigan Comprehensive Cancer Center, Ann Arbor

University of Michigan Health System, Ann Arbor

University of Illinois Cancer Center, Chicago

University of Nebraska Medical Center, Omaha

Rutgers Cancer Institute of New Jersey, New Brunswick